Last reviewed · How we verify
Dapagliflozin Oral Product
Dapagliflozin Oral Product is a Small molecule drug developed by Vastra Gotaland Region. It is currently FDA-approved. Also known as: SGLT2 inhibitor.
At a glance
| Generic name | Dapagliflozin Oral Product |
|---|---|
| Also known as | SGLT2 inhibitor |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) (PHASE3)
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin Oral Product CI brief — competitive landscape report
- Dapagliflozin Oral Product updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI
Frequently asked questions about Dapagliflozin Oral Product
What is Dapagliflozin Oral Product?
Dapagliflozin Oral Product is a Small molecule drug developed by Vastra Gotaland Region.
Who makes Dapagliflozin Oral Product?
Dapagliflozin Oral Product is developed and marketed by Vastra Gotaland Region (see full Vastra Gotaland Region pipeline at /company/vastra-gotaland-region).
Is Dapagliflozin Oral Product also known as anything else?
Dapagliflozin Oral Product is also known as SGLT2 inhibitor.
What development phase is Dapagliflozin Oral Product in?
Dapagliflozin Oral Product is FDA-approved (marketed).
Related
- Manufacturer: Vastra Gotaland Region — full pipeline
- Also known as: SGLT2 inhibitor
- Compare: Dapagliflozin Oral Product vs similar drugs
- Pricing: Dapagliflozin Oral Product cost, discount & access